Viking Therapeutics (VKTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Viking Therapeutics (VKTX)
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Key Insights
Critical company metrics and information
Share Price
$50.35Market Cap
$5.61 BillionTotal Outstanding Shares
111.44 Million SharesTotal Employees
34Dividend
No dividendIPO Date
April 29, 2015SIC Description
Pharmaceutical PreparationsHomepage
https://www.vikingtherapeutics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $611.65 Million |
Net Cash Flow From Operating Activities | $-74.25 Million |
Net Cash Flow, Continuing | $13.19 Million |
Net Cash Flow From Operating Activities, Continuing | $-74.25 Million |
Net Cash Flow From Investing Activities, Continuing | $-524.22 Million |
Net Cash Flow From Investing Activities | $-524.22 Million |
Net Cash Flow From Financing Activities | $611.65 Million |
Net Cash Flow | $13.19 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Operating Expenses | $42.81 Million |
Basic Average Shares | $326.62 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $-99.15 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-99.15 Million |
Operating Expenses | $133.97 Million |
Revenues | $0.00 |
Basic Earnings Per Share | $-0.93 |
Income/Loss From Continuing Operations Before Tax | $-99.15 Million |
Operating Income/Loss | $-133.97 Million |
Diluted Average Shares | $326.62 Million |
Net Income/Loss | $-99.15 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Research and Development | $91.16 Million |
Income/Loss From Continuing Operations After Tax | $-99.15 Million |
Diluted Earnings Per Share | $-0.93 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $25.68 Million |
Current Assets | $936.65 Million |
Liabilities | $26.44 Million |
Accounts Payable | $254,000.00 |
Other Current Liabilities | $25.43 Million |
Noncurrent Liabilities | $755,000.00 |
Equity Attributable To Noncontrolling Interest | $0.00 |
Noncurrent Assets | $1.24 Million |
Equity | $911.45 Million |
Liabilities And Equity | $937.89 Million |
Equity Attributable To Parent | $911.45 Million |
Assets | $937.89 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Viking Therapeutics (VKTX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.